Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-Lactamase Enzyme (Ambler Class D) (OXA)
- Target
- OXA
- Molecular classification
- Enzyme, Hydrolase, Beta-lactamase, Ambler Class D Beta-Lactamase, Serine Beta-Lactamase
01
Overview
Class D beta-lactamases, also known as oxacillinases (OXA-type enzymes), are serine-based enzymes that hydrolyze beta-lactam antibiotics, conferring resistance. They are particularly problematic in pathogens like Acinetobacter baumannii and some Enterobacteriaceae, contributing to multidrug resistance. These enzymes inactivate beta-lactam antibiotics by hydrolyzing the beta-lactam ring, preventing the drugs from inhibiting penicillin-binding proteins (PBPs) essential for bacterial cell wall synthesis. Common variants include OXA-1/30, OXA-10, OXA-23, OXA-24/40, and OXA-48, which may exhibit different substrate specificities, including carbapenemase activity. Many clinically used beta-lactamase inhibitors are ineffective against Class D enzymes, making infections difficult to treat.
- Other names
- OxacillinaseOXA-type beta-lactamaseClass D beta-lactamase
02
Mechanism of action
Hydrolyzes the beta-lactam ring of beta-lactam antibiotics, inactivating them and preventing them from inhibiting penicillin-binding proteins (PBPs).
03
Biological functions
Hydrolysis of beta-lactam antibioticsDrug resistance
04
Disease associations
Antibiotic resistanceInfection
05
Safety considerations
Multidrug resistanceTreatment failure of bacterial infectionsLimited effectiveness of beta-lactamase inhibitors
06
Interacting drugs
Penicillins
4 more in the full profile.
Beyond the preview
Go deeper on Beta-Lactamase Enzyme (Ambler Class D) (OXA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beta-Lactamase Enzyme (Ambler Class D) (OXA).